Vimarsana
Biggest News Aggregation in the World

Page 2 - Accelerate Commercialization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accelerate Commercialization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accelerate Commercialization Today - Breaking & Trending Today

MindMaze Secures $125M to Accelerate Commercialization of Digital Neurotherapeutics Platform - Vimarsana News

MindMaze Secures $125M to Accelerate Commercialization of Digital Neurotherapeutics Platform

MindMaze, a SaaS-based digital neurotherapeutics platform raises $125M led by AlbaCore Capital Group to expand neuro-rehabilitation platform.

Plus, a Global Provider of Self-Driving Truck Technology, to Become Publicly Listed Through Business Combination with Hennessy Capital Investment Corp. V - Vimarsana News

Plus, a Global Provider of Self-Driving Truck Technology, to Become Publicly Listed Through Business Combination with Hennessy Capital Investment Corp. V

Share: Autonomous Trucking Technology Company Plans to Start Mass Production in 2021 Proprietary Full-Stack Level 4 ("L4") Software is Behind the Decision-Making Required to Autonomously, Safely and Intelligently Drive the Vehicle Post-Combination Represents Market Capitalization of $3.3 Billion for Plus Plus to Add Up to Approximately $500 Million in Gross Proceeds to Accelerate Commercialization and Expand Global Operations Transaction Supported by $150 Million PIPE, Including Investments From Funds and Accounts Managed by BlackRock and the D. E. Shaw Group, Among Other Institutional Invest...

Roche's arthritis drug Actemra scores FDA nod in rare autoimmune disease after partial clinical win - Vimarsana News

Roche's arthritis drug Actemra scores FDA nod in rare autoimmune disease after partial clinical win

Mar 5, 2021 11:20am Roche's Actemra has become the first biologic that the FDA approved for patients with systemic sclerosis-associated interstitial lung disease. (Roche/Genentech) Missed the primary endpoint of a clinical trial? No problem. We’ll pick the study apart and approve your drug based on a post-hoc subgroup analysis. That’s what the FDA did in granting Roche’s Actemra a go-ahead in patients with interstitial lung disease (ILD) associated with the rare autoimmune disease systemic sclerosis (SSc). The approval makes Actemra the first biologic drug cleared by the FDA to slow ...

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi - Vimarsana News

Novartis exec says Kymriah's ready to square off with Bristol Myers' new CAR-T rival Breyanzi

Mar 5, 2021 11:23am Novartis' Kymriah is ready for new CAR-T competition from Bristol Myers Squibb, an exec said. (Novartis) With the FDA’s recent approval for Bristol Myers Squibb’s Breyanzi, a new pharma giant is entering the CAR-T lymphoma fray. But with new, impressive real-world data and a global manufacturing expansion under its belt, rival Novartis says it's ready to rumble. Novartis last year opened CAR-T production sites in Switzerland and France, while a partner opened a facility in Japan. Another partner, Cell Therapies, has since opened the first CAR-T manufacturing site in...

Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use - Vimarsana News

Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use

Mar 3, 2021 9:55am Novartis presented positive study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum from nurses and patients using its Kesimpta auto-injector pen for MS. (Novartis) Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses. Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over riv...